Two major domestic drug makers in China have pulled off a "quantum leap" to rake in more revenues from innovative drugs than generic medications in the first half, amid the national industry’s ongoing pivot to novelty.
In the first six months of 2022, Hong Kong-listed Simcere Pharmaceutical Group booked fully 65% of its sales from the innovative drug segment,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?